甲磺酸阿帕替尼治疗晚期恶性肿瘤45例  

Treatment of 45 patients with advanced malignant tumors with apatinib mesylate

作　　者：刘飞[1] 赵文英[2] 陈小雪 LIU Fei;ZHAO Wenying;CHEN Xiaoxue(Department of Oncology,Chizhou Second People's Hospital,Chizhou,Anhui,247000,China;Department of Oncology,Yijishan Hospital Affiliated to Wannan Medical College,Wuhu,Anhui,241000,China)

机构地区：[1]池州市第二人民医院肿瘤内科,安徽池州247000 [2]皖南医学院附属弋矶山医院肿瘤内科,安徽芜湖241000

出　　处：《安徽医药》2021年第3期593-595,共3页Anhui Medical and Pharmaceutical Journal

基　　金：安徽省自然科学基金(1708085MH202)。

摘　　要：目的探讨在晚期恶性肿瘤病人中应用甲磺酸阿帕替尼的疗效及安全性。方法选择2017年8月1日至2019年7月31日池州市第二人民医院接受单药甲磺酸阿帕替尼靶向治疗或联合化疗方案的51例晚期恶性肿瘤病人进行回顾性分析,对近期疗效及生存状况进行评估,并观察不良反应的发生情况。结果45例病人可评估疗效,无完全缓解(CR)病例,部分缓解(PR)12例,稳定(SD)15例和进展(PD)18例,客观缓解率(ORR)和疾病控制率(DCR)分别为26.67%和60.00%,中位无进展生存(PFS)4个月,中位总生存(OS)7个月;不良反应有高血压(44.44%)、蛋白尿(31.11%)、手足综合征(26.67%)、胆红素升高(22.22%)、转氨酶升高(20.00%)及胃肠道反应(11.11%)等,大多为1~2级,严重不良反应发生率低。结论针对晚期恶性肿瘤应用阿帕替尼靶向治疗具有一定的疗效,病人能够耐受,安全性高。Objective To investigate the efficacy and safety of apatinib mesylate in patients with advanced malignant tumors.Meth⁃ods 51 patients with advanced malignant tumors were selected for retrospective analysis from August 1,2017 to July 31,2019 in Chi⁃zhou Second People's Hospital.They were treated with single drug apatinib mesylate,or combined chemotherapy.The short-term effica⁃cy and survival status were evaluated,and the occurrence of adverse reactions was observed.Results 45 patients were evaluated for the curative effect.There were no CR cases,12 PR cases,15 SD cases and 18 PD cases.ORR and DCR were 26.67%and 60.0%re⁃spectively.The median PFS was 4 months and the median OS was 7 months.Adverse reactions included hypertension(44.44%),protein⁃uria(31.11%),hand-foot syndrome(26.67%),bilirubin elevation(22.22%),transaminase elevation(20.00%),and gastrointestinal reac⁃tions(11.11%),etc.Most of them were 1-2 levels,and the incidence of severe adverse reactions was low.Conclusion Apatinib mesyl⁃ate is effective and safe in the treatment of advanced malignant tumors.The patient can tolerate.

关 键 词：甲磺酸阿帕替尼 肿瘤 分子靶向治疗 疗效 安全性 

分 类 号：R730.5[医药卫生—肿瘤]